



## Emerging Therapies in Renal Cell Carcinoma

Guest Editors:

**Dr. Matthew T Campbell**

Department of Genitourinary  
Medical Oncology, University of  
Texas MD Anderson Cancer  
Center, Houston, TX, USA

**Dr. Tian Zhang**

Hematology and Oncology  
Division, Department of Internal  
Medicine, University of Texas  
Southwestern (UTSW), Dallas, TX,  
USA

Deadline for manuscript  
submissions:

**closed (31 December 2022)**

### Message from the Guest Editors

Dear Colleagues,

Therapy for renal cell carcinoma has evolved rapidly in the last decade with the development of modern immunoncology (IO) agents and second-generation tyrosine kinase inhibitors (TKI). Combinations of these agents have emerged as standard of care front line treatment for patients with metastatic clear cell histology. Adjuvant IO therapy has now emerged as an option for high-risk localized patients after surgery. The role of cytoreductive nephrectomy has been called into question, but the role of cytoreductive nephrectomy, metastasectomy, ablative techniques, and radiation continue to play important roles in select patients. Therapeutic options are also advancing for patients with non-clear cell histologies. For the first time patients with hereditary cancer syndrome, Von Hippel Lindau, have an approved therapeutic option.

We are pleased to invite you to contribute to this special issue focused on the multitude of therapeutic advances in renal cell carcinoma (RCC).

For further reading, please, visit the [Special Issue website](#)





# cancers



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Samuel C. Mok**

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

## Contact Us

*Cancers* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
X@Cancers\_MDPI